Trials / Terminated
TerminatedNCT02448589
An Investigation of TAS-119 Monotherapy
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Taiho Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
Detailed description
This is a Phase 1, open-label, non-randomized, dose escalation study of TAS-119 evaluating the safety, tolerability, PK, pharmacogenomics, pharmacodynamics, and preliminary antitumour activity in patients with advanced and unresectable solid tumours. The study will evaluate TAS-119 monotherapy, employing two sequential phases. * A Dose Escalation Phase * An Expansion Phase
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-119 |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2015-05-19
- Last updated
- 2024-09-04
Locations
6 sites across 5 countries: United States, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02448589. Inclusion in this directory is not an endorsement.